EDTA Red Cell Diluent for Immunoassay False Positives

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Automated immunoassays for detecting red blood cell antibodies often produce false positive or equivocal results, leading to unnecessary further testing and donor searches, due to the inability to accurately distinguish between negative and positive samples.

Innovation Solution

Incorporating ethylenediaminetetraacetic acid (EDTA) into the red cell diluent at concentrations of 3-5 g/L to prepare capture plates, which reduces the rate of false positive results by stabilizing and immobilizing red blood cell fragments, thereby improving the specificity of antibody detection.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If automated systems are used to perform immunoassays, then the speed of performing assays is increased, but false positive results increase

Engineering Contradiction:

Improveassay speedVSAvoidfalse positive rate

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

EDTA is introduced as an intermediary substance in the RBC diluent to mediate between the automated assay system and the biological samples. It specifically targets and chelates divalent cations that mediate non-specific binding, thereby reducing false positives while maintaining automated assay functionality

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The chemical composition parameter of the RBC diluent is changed by adding EDTA at concentrations of 0.5-10 mM. This parameter change modifies the ionic environment to reduce non-specific binding interactions, thereby improving assay reliability without compromising automated processing speed

Inventive Principle:

Principle #35Parameter changes

2Measurement precision

If RBC fragments are immobilized to the well surface, then antibody detection is enabled, but non-specific binding increases causing false positives

Engineering Contradiction:

Improveantibody detection accuracyVSAvoidnon-specific binding

Core Design Contradiction:

Measurement precisionVSObject-generated harmful factors

Solution Approach 1:

EDTA acts as an intermediary that selectively binds divalent cations (Ca2+, Mg2+) that are often involved in non-specific binding interactions. By chelating these cations, EDTA prevents non-specific binding while allowing specific antibody-antigen interactions to proceed, thereby improving measurement precision

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent converts the potentially harmful effect of divalent cations (which cause non-specific binding and false positives) into a beneficial effect by using EDTA to selectively chelate them. This transforms the problem of cation-mediated non-specific binding into a solution where controlled chelation enhances assay specificity

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The use of EDTA in the red cell diluent significantly decreases the occurrence of false positive results in automated hemagglutination assays, enhancing the accuracy of antibody detection and reducing the need for additional testing.

Implementation Method 1

RBC diluent may include a chelating agent, such as ethylenediaminetetraacetic acid (EDTA), for example, disodium EDTA and/or tetrasodium EDTA

Methodology Applied

Scientific EffectChelation:

Data Source

PatentUS20230375574A1Red cell diluent with chelating agent and methods for making and using the same

Publication Date: 2023.11.23 IMMUCOR INC

AI summary

The present disclosure relates to a RBC solution comprising ethylenediaminetetraacetic acid (EDTA) and methods for making and using the same. The solution can comprise EDTA at a concentration from 3-5 g/L, including 4 g/L. Well plates prepared using the solution can provide a decreased rate of false positive results in automated immunoassays for detecting RBC antibodies in a patient sample.